Science-led biopharmaceutical company AstraZeneca PLC (LSE: AZN) (STO: AZN) (Nasdaq: AZN) announced on Monday that Ultomiris, a long-acting C5 complement inhibitor, has gained FDA approval for treating adults with anti-AQP4 antibody-positive neuromyelitis optica spectrum disorder (NMOSD), offering relapse-free potential.
The CHAMPION-NMOSD Phase III trial demonstrates significant relapse risk reduction.
NMOSD, a rare autoimmune disease affecting the central nervous system, sees a diagnosed prevalence of around 6,000 adults in the US. Ultomiris's safety profile remains consistent, with no new adverse events observed.
Ultomiris, already approved in Japan and the EU for NMOSD, inhibits the complement cascade to prevent attacks on healthy cells.
AstraZeneca's rare disease-focused Alexion group leads the development of Ultomiris, aiming to serve patients with rare and devastating conditions globally.
PTC Therapeutics submits vatiquinone NDA to US FDA
Mitsubishi Tanabe Pharma forms research collaboration with Dewpoint Therapeutics
IXICO signs commercial agreement with PETNET Solutions to enhance neuroimaging capabilities
Newron and EA Pharma sign licensing deal for Evenamide in Asia
Cybin selects Facet Life Sciences as US regulatory partner
GC Biopharma and Novel Pharma report first patient dosed in multinational trial of GC1130A
Merck's WELIREG approved in China for VHL disease
AbbVie signs new discovery, co-development and licence agreement with Gedeon Richter
JCR Pharmaceuticals showcases preclinical gene therapy advances at ESGCT Congress